DTOR
Sacramento · Founded 2014
About DTOR
At DtoR they have developed the PCR of gene expression’a disruptive technology that will revolutionize the tools used to “tune” protein production in any organism. In one step, and for any cell type, they can identify all of the switches regulating expression of the genome, as well as how active they are. They can also rapidly evolve or synthesize new switches to adapt to any application. Applications developed using their platform will lead to improved product yields in bioreactors, engineered specialty crops, optimized cancer therapeutics, and much more. The possibilities are limited only by their partners' imaginations.
Company Facts
- Founded: 2014
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $250.0K
- Funding stage: Seed
- Last round: Pre-Seed (Sep 2015)
- Website: dtorinc.com
Canonical: https://fsome.com/organization/dtor-8311470 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.